2,545 reports of this reaction
2.4% of all PIMAVANSERIN TARTRATE reports
#7 most reported adverse reaction
DELUSION is the #7 most commonly reported adverse reaction for PIMAVANSERIN TARTRATE, manufactured by Acadia Pharmaceuticals Inc.. There are 2,545 FDA adverse event reports linking PIMAVANSERIN TARTRATE to DELUSION. This represents approximately 2.4% of all 106,130 adverse event reports for this drug.
PIMAVANSERIN TARTRATE has an overall safety score of 85 out of 100. Patients taking PIMAVANSERIN TARTRATE who experience delusion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DELUSION is a less commonly reported adverse event for PIMAVANSERIN TARTRATE, but still significant enough to appear in the safety profile.
In addition to delusion, the following adverse reactions have been reported for PIMAVANSERIN TARTRATE:
The following drugs have also been linked to delusion in FDA adverse event reports:
DELUSION has been reported as an adverse event in 2,545 FDA reports for PIMAVANSERIN TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DELUSION accounts for approximately 2.4% of all adverse event reports for PIMAVANSERIN TARTRATE, making it a notable side effect.
If you experience delusion while taking PIMAVANSERIN TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.